Global Mesenchymal Stem Cells Revenue Is About 110 M USD In 2015
Tuesday, 23 Oct, 2018
Mesenchymal Stem Cells (MSC), also termed Mesenchymal Stromal Cells, are multipotent cells that can differentiate into a variety of cell types and have the capacity for self-renewal. MSC have been shown to differentiate in vitro or in vivo into adipocytes, chondrocytes, osteoblasts, myocytes, neurons, hepatocytes, and pancreatic islet cells. Optimized PromoCell media are available to support both the growth of MSC and their differentiation into several different lineages. Recent experiments suggest that differentiation capabilities into diverse cell types vary between MSC of different origin.

In the last several years, Global market of Mesenchymal Stem Cells developed rapidly, with an average growth rate of 6.2%. In 2015, Global revenue of Mesenchymal Stem Cells is about 110 M USD.

The global average gross margin of Mesenchymal Stem Cells is in the fluctuation trend, from 70% in 2012 to 67% in 2016. With the situation of global economy, gross margin will be in decreasing trend in the following five years.

The type of Mesenchymal Stem Cells includes Human, Mouse, Rat. The proportion of Human in 2015 is about 39%, and the proportion of Mouse in 2016 is about 31%. 

Mesenchymal Stem Cells are widely sold in Research Institutes and Hospitals segment. The most proportion of Mesenchymal Stem Cells are sold in Research Institutes and the market share in 2016 is about 76%, but the Hospitals have upstream trend.

North America region is the largest consumption of Mesenchymal Stem Cells, with a sales revenue market share nearly 41% in 2016. Europe is the second largest consumer of Mesenchymal Stem Cells, enjoying sales revenue market share about 31% in 2016.Market competition is intense between the region’s research institutes and hospital. In the future, the hospital will have larger market share.